Weighting must wait: incorporating equity concerns into cost effectiveness analysis may take longer than expected

Current practice in economic evaluation is to assign equal social value to a unit of health improvement (“a QALY is a QALY is a QALY”). Alternative views of equity are typically considered separately to efficiency. One proposal seeks to integrate these two sets of societal concerns by attaching equity weights to QALYs. To date, research in pursuit of this goal has focussed on candidate equity criteria and methods for estimating such weights. It has implicitly been assumed that should legitimate, valid, and reliable equity weights become available, it would be a straightforward task to incorporate them into as a separate simple calculation after estimating cost per unweighted QALY. This paper suggests that in many situations these simple approaches to incorporating equity weights will not appropriately reflect the preferences on which the weights are based and therefore equity weights must be incorporated directly into the cost effectiveness analysis. In addition to these technical issues, there are a number of practical challenges that arise from the movement from implicit to explicit consideration of equity. Equity weights should be incorporated in economic evaluation, but not until these challenges have been appropriately addressed

Orphan drugs and the NHS: Should we value rarity

Cost effectiveness plays an important part in current decisions about the funding of health technologies. Drugs for rare disease (orphan drugs) are often expensive to produce and, by definition, will benefit only small numbers of patients. Several countries have put measures in place to safeguard research and development of orphan drugs, but few get close to meeting the cost effectiveness criteria for funding by healthcare providers. We examine the justifications for special status for rare diseases and ask whether the cost effectiveness of drugs for rare or very rare diseases should be treated differently from that of other drugs and interventions

Drugs for exceptionally rare diseases: a commentary on Hughes et al

Recently in this journal, Hughes and colleagues discussed special funding status to ultra-orphan drugs. They concluded that there should be a uniform policy for the provision of orphan drugs across Europe; that complete restriction was impractical, and that UK policy should aspire to the values of the EU directive on orphan drugs. We critically assess these arguments, demonstrating that they failed to justify special status for treatments for rare diseases

Does the value of quality of life depend on duration?

The aims of this study are to investigate the feasibility of eliciting Time Trade Off (TTO) valuations using short durations; to determine the effect of contrasting durations on individuals’ responses to the TTO; to examine variations within and between respondents’ values with respect to duration; and to consider the insights provided by participants’ comments and explanations regarding their reaction to duration in the valuation task. 27 participants provided TTO values using short and long durations for three EQ-5D states. Feedback was sought using a series of open ended questions. Of the 81 opportunities to observe it, strict constant proportionality was satisfied twice. 11 participants had no systematic relationship between duration and value; 11 provided consistently lower valuations in long durations, while 5 had higher valuations in long durations. Comments provided by participants were consistent with the values they provided. Mean TTO values did not differ markedly between alternative durations. We conclude that it is feasible to elicit TTO values for short durations. There is considerable heterogeneity in individuals’ responses to the time frames used to elicit values. Further research is required to ensure that the values used in cost effectiveness analysis adequately represent preferences about quality and length of life

Weighting must wait: incorporating equity concerns into cost effectiveness analysis may take longer than expected

Current practice in economic evaluation is to assign equal social value to a unit of health improvement (“a QALY is a QALY is a QALY”). Alternative views of equity are typically considered separately to efficiency. One proposal seeks to integrate these two sets of societal concerns by attaching equity weights to QALYs. To date, research in pursuit of this goal has focussed on candidate equity criteria and methods for estimating such weights. It has implicitly been assumed that should legitimate, valid, and reliable equity weights become available, it would be a straightforward task to incorporate them into as a separate simple calculation after estimating cost per unweighted QALY. This paper suggests that in many situations these simple approaches to incorporating equity weights will not appropriately reflect the preferences on which the weights are based and therefore equity weights must be incorporated directly into the cost effectiveness analysis. In addition to these technical issues, there are a number of practical challenges that arise from the movement from implicit to explicit consideration of equity. Equity weights should be incorporated in economic evaluation, but not until these challenges have been appropriately addressed

A uniform Time Trade Off method for states better and worse than dead: feasibility study of the ‘lead time’ approach

The way Time Trade Off (TTO) values are elicited for states of health considered ‘worse than being dead’ has important implications for the mean values used in economic evaluation. Conventional approaches to TTO, as used in the UK’s ‘MVH’ value set, are problematic because they require fundamentally different tradeoffs tasks for the valuation of states better and worse than dead. This study aims to refine and test the feasibility of a new approach described by Robinson and Spencer (2006), and to explore the characteristics of the valuation data it generates. The approach introduces a ‘lead time’ into the TTO, producing a uniform procedure for generating values either >0 or <0. We used this lead time TTO to value 10 moderate to severe EQ-5D states using a sample of the general public (n=109). We conclude that the approach is feasible for use in valuation studies, and appears to overcome the discontinuity in values around 0 evident in conventional methods. However, further research is required to resolve the issue of how to handle participants who ‘use up’ all lead time; to develop ways of controlling for individual time preferences; and to better understand the implications for valuations of states better than dead

Weighting must wait: incorporating equity concerns into cost effectiveness analysis may take longer than expected

Current practice in economic evaluation is to assign equal social value to a unit of health improvement (“a QALY is a QALY is a QALY”). Alternative views of equity are typically considered separately to efficiency. One proposal seeks to integrate these two sets of societal concerns by attaching equity weights to QALYs. To date, research in pursuit of this goal has focussed on candidate equity criteria and methods for estimating such weights. It has implicitly been assumed that should legitimate, valid, and reliable equity weights become available, it would be a straightforward task to incorporate them into as a separate simple calculation after estimating cost per unweighted QALY. This paper suggests that in many situations these simple approaches to incorporating equity weights will not appropriately reflect the preferences on which the weights are based and therefore equity weights must be incorporated directly into the cost effectiveness analysis. In addition to these technical issues, there are a number of practical challenges that arise from the movement from implicit to explicit consideration of equity. Equity weights should be incorporated in economic evaluation, but not until these challenges have been appropriately addressed

Transport mechanism through metal-cobaltite interfaces

The resistive switching (RS) properties as a function of temperature were studied for Ag/La$_{1-x}$Sr$_x$CoO$_3$ (LSCO) interfaces. The LSCO is a fully-relaxed 100 nm film grown by metal organic deposition on a LaAlO$_3$ substrate. Both low and a high resistance states were set at room temperature and the temperature dependence of their current-voltage (IV) characteristics was mea- sured taking care to avoid a significant change of the resistance state. The obtained non-trivial IV curves of each state were well reproduced by a circuit model which includes a Poole-Frenkel element and two ohmic resistances. A microscopic description of the changes produced by the RS is given, which enables to envision a picture of the interface as an area where conductive and insulating phases are mixed, producing Maxwell-Wagner contributions to the dielectric properties.Comment: 13 pages, 5 figures, to be published in APL. Corresponding author: C. Acha ([email protected]